Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)

Westhovens R.; Taylor P. C.; Alten R.; Pavlova D.; Enriquez-Sosa F.; Mazur M.; Greenwald M.; Van der Aa A.; Vanhoutte F.; Tasset C.; Harrison P.

首页> 外文期刊>Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research >Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)

【24h】

Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)

机译：菲尔替尼（GLPG0634 / GS-6034）是口腔jak1选择性抑制剂，与甲氨蝶呤（MTX）组合有效的类风湿性关节炎，对MTX的反应不充分：随机剂量寻找研究（Darwin 1）的结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objectives To evaluate the efficacy and safety of different doses and regimens of filgotinib, an oral Janus kinase 1 inhibitor, as add-on treatment to methotrexate (MTX) in patients with active rheumatoid arthritis (RA) and inadequate response to MTX.

机译：目的评价菲霉素，口腔Kinase 1抑制剂的不同剂量和方案的疗效和安全性，作为有活性类风湿性关节炎（RA）的患者中对甲氨蝶呤（MTX）的加入治疗和对MTX的反应不足。

著录项

来源
《Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research》 |2017年第6期|共11页
作者
Westhovens R.; Taylor P. C.; Alten R.; Pavlova D.; Enriquez-Sosa F.; Mazur M.; Greenwald M.; Van der Aa A.; Vanhoutte F.; Tasset C.; Harrison P.;
展开▼
作者单位

Skeletal Biol &

Engn Res Ctr Dept Dev &

Regenerat KU B-3000 Leuven Belgium;

Univ Oxford Nuffield Dept Orthopaed Rheumatol &

Musculoskele Oxford England;

Schlosspark Klin Innere Med II Berlin Germany;

LTD M&

M CENTRS Adazi Latvia;

CLINSTILE SA DE CV Mexico City DF Mexico;

IMSP Inst Cardiol Kishinev Moldova;

Desert Med Adv Palm Desert CA USA;

Galapagos NV Mechelen Belgium;

Galapagos NV Mechelen Belgium;

Galapagos NV Mechelen Belgium;

Galapagos NV Mechelen Belgium;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类免疫性疾病;
关键词

相似文献

外文文献

1. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1) [J] . Westhovens R., Taylor P. C., Alten R., Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2017,第6期

机译：菲尔替尼（GLPG0634 / GS-6034）是口腔jak1选择性抑制剂，与甲氨蝶呤（MTX）组合有效的类风湿性关节炎，对MTX的反应不充分：随机剂量寻找研究（Darwin 1）的结果
2. Methotrexate (MTX) Plus Hydroxychloroquine versus MTX Plus Leflunomide in Patients with MTX-Resistant Active Rheumatoid Arthritis: A 2-Year Cohort Study in Real World [J] . Le Zhang, Fangfang Chen, Shikai Geng, Journal of Inflammation Research . 2020,第4期

机译：甲氨蝶呤（MTX）加羟氯喹对MTX抗性活性类风湿性关节炎患者的羟基氯喹（MTX Plus Leflunomide）：一个2年的队列在现实世界中的研究
3. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). [J] . Emery P, Deodhar A, Rigby WF, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2010,第9期

机译：不同剂量的利妥昔单抗的疗效和安全性以及复治的利妥昔单抗：一项针对具有生物学活性的类风湿性关节炎且对甲氨蝶呤反应不充分的患者的安慰剂对照随机对照试验（研究评估利妥昔单抗在MTX iN不足的rEsponders（SERENE）中的疗效）。
4. Methotrexate (MTX) Plus Hydroxychloroquine versus MTX Plus Leflunomide in Patients with MTX-Resistant Active Rheumatoid Arthritis: A 2-Year Cohort Study in Real World [O] . Le Zhang, Fangfang Chen, Shikai Geng, 2020

机译：甲氨蝶呤（MTX）加羟氯喹对MTX抗性活性类风湿性关节炎患者的羟基氯喹（MTX Plus Leflunomide）：一个2年的队列在现实世界中的研究
5. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study [O] . Westhovens, R, Taylor, P, Alten, R, 2016

机译：Filgotinib（GLPG0634 / GS-6034），一种口服JAK1选择性抑制剂，与活动性类风湿性关节炎且对MTX反应不足的患者有效结合甲氨蝶呤（MTX）：一项随机的剂量研究研究结果

Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)

摘要

著录项

相似文献

相关主题

期刊订阅